Evidence-based laboratory medicine is the practice of utilizing the best available evidence to guide the selection, interpretation, and application of laboratory tests to assist clinical decision making and improve individual patient care and outcomes. This promotes the effective use of healthcare resources. Appropriate laboratory test utilisation involves ordering the right test on the right patient at the right time and more than 70% of clinical decisions are reliant on laboratory results. Health-care systems globally are under increasing pressure to reduce costs while continuously providing quality and efficient care. Diabetes mellitus is also known as the “silent” epidemic as cases are increasing worldwide and many of these are undiagnosed. Of concern, cases are increasing in low- and middle-income countries especially in sub Saharan Africa and South-East Asia. This webinar is presented by members of the IFCC Committees for Evidence-based Laboratory Medicine (C-EBLM) and Education on the Use of Biomarkers in Diabetes (C-EUBD). We will look at two markers of glycaemic control, namely HbA1c and Glycated Albumin (GA) and provide the evidence for the use of these tests. Finally, the high rates of diabetes mellitus in developing countries will be discussed as well as the value of laboratory testing in these countries.

This webinar comprises of three following presentations of 20 min each followed by 20 min of panel discussion at the end.

Chair: Prof. Andrew Don-Wauchope

Talk 1- "HbA1c– pros and cons" - Dr. Emma English

Talk 2- "Glycated albumin – what is the evidence?" - Prof. Annalise Zemlin

Talk 3- "Laboratory Diagnosis and Management of Diabetes Mellitus - Does Global Evidence Warrant Population-wise Differences" - Dr. Prof. Seema Bhargava

Please feel free to share this event in your social media with #IFCCLive Webinars.

Click here to convert to your time zone